AB0453

RED RICE YEAST. AN ALTERNATIVE IN RHEUMATOID ARTHRITIS AND HYPERLIPIDEMIA

Blanca Varas¹, María Martín Fuentes². ¹Universitary Santa Cristina Hospital, Rheumatology, Madrid, Spain; ²Universitary Santa Cristina Hospital, Endocrinology, Madrid, Spain

Background: Lipid profile control is essential in patients diagnosed with inflammatory disease such as rheumatoid arthritis (RA), since cardiovascular events (CV) are still the first cause of mortality. According to the EULAR recommendations on CV risk, in those patients with a low or moderate CV risk index, for whom diet and exercise have not been effective to diminish low density lipoprotein (LDL) cholesterol below 190 and 100 respectively, we must prescribe a statin. These are the most commonly used drugs with undoubted benefits shown in medical literature. However, often-polymedicated patients may present intolerances or adverse side effects that limit their use. Red rice yeast, whose main active ingredient is monacolin K, has been used in traditional Chinese medicine since 800 AD as a remedy to reduce the total cholesterol level (TC) in blood, LDL and triglycerides (TG). In addition, some studies underline its anti-inflammatory effect and its benefit in patients with inflammatory pathology. In recent years, its use has spread throughout the western world.

Objectives: To evaluate the efficacy of red rice yeast in patients with elevated levels of TC and LDL in rheumatology clinic.

Methods: Prospective study that includes two cohorts of 30 patients with similar demographic characteristics. One cohort with RA patients and the other one without inflammatory disease. Both groups present high levels of TC and LDL. We study the demographic, clinical and lipid levels. A standard dose of red rice yeast is administered to every patient and we evaluate the analytical response after 3 and 6 months of treatment. For the statistical analysis, we used the SPSS program 22.0 version. Quantitative variables are presented as means $\pm$ standard deviation and qualitative variables as percentages. The comparisons between the quantitative variables are made with the Student's T-test. We compared the mean values for each visit with the Anova test. A $p < 0.05$ is considered significant.

Results: In the group of patients without inflammatory pathology ($n = 30$), 73% are women with an average age of 63.9 ± 7 years. The mean of baseline TC is $265.2 \text{ mg/dL} \pm 13.7$ and LDL 176.4 ± 16 . After 3 and 6 months of treatment, a significant decrease in both values was obtained (TC 231 ± 19 and 209.8 ± 19 F: 26.71 p 0.000 and LDL 143.9 ± 20 and 123.6 ± 19 F: 22.51 p 0.000)

In the cohort of patients with RA ($n = 30$), 66% were women with an average age of 62.1 ± 10 . The mean baseline TC is 258.2 ± 14 and LDL is 176.7 ± 10 . After 3 and 6 months of treatment a significant decrease of both values was obtained (TC 224 ± 24 and 196.1 ± 28 F: 21.55 p 0.000 LDL 149.5 ± 12 and 122.4 ± 25 F: 28.28 p 0.000)

There were no significant changes in HDL or TG levels. Neither adverse effects were detected nor treatment was abandoned.

Conclusion: The red rice yeast significantly decreases the levels of TC and LDL in the two cohorts. In patients with RA and mild or moderate CV risk, where a close control is necessary, the use of red rice yeast could be an effective therapeutic alternative free of adverse side effects. More studies are needed with a greater number of patients to corroborate these data

REFERENCES

- [1] Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update *Annals of the Rheumatic Diseases* 2017;76:17-28.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.7836

AB0454

FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY

Ara Dikranian¹, Jürgen Wollenhaupt², Valderilio F. Azevedo³, Louis Bessette⁴, David Gold⁵, Jose Luis Rivas⁶, Harry Shi⁷, Lisy Wang⁸, John Woolcott⁷, Andrea Shapiro⁹, Peter Nash¹⁰. ¹Cabrillo Center for Rheumatic Disease, San Diego, CA, United States of America; ²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany; ³Universidade Federal do Paraná, Curitiba, Brazil; ⁴Laval University, Kirkland, QC, Canada; ⁵Pfizer Canada, Montreal, QC, Canada; ⁶Pfizer SLU, Madrid, Spain; ⁷Pfizer Inc, Collegeville, PA, United States of America; ⁸Pfizer Inc, Groton, CT, United States of America; ⁹Pfizer Inc, Peapack, NJ, United States of America; ¹⁰University of Queensland, Brisbane, Australia

Background: Tolerability remains ill-defined in clinical trials and commonly refers to non-serious adverse events (AEs) impacting patient (pt) satisfaction and treatment adherence. Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).

Objectives: This update to a previously published post hoc analysis¹ describes the frequency and duration of the most common tolerability-related non-serious AEs in pts with RA receiving tofacitinib 5 mg BID as monotherapy or with conventional synthetic (cs)DMARDs in Phase (P)3 and P3b/4 studies.

Methods: Data were pooled from: ORAL Step (NCT00960440); ORAL Solo (NCT00814307); ORAL Scan (NCT00847613); ORAL Sync (NCT00856544); ORAL Standard (NCT00853385); and ORAL Strategy (NCT02187055). This post hoc analysis included data from pts receiving tofacitinib 5 mg BID monotherapy (ORAL Solo, ORAL Strategy), placebo (PBO; ORAL Solo), or tofacitinib 5 mg BID or PBO with csDMARDs (all studies except ORAL Solo). Non-serious AEs (affecting pts' day-to-day experience and ability to tolerate therapy) with incidence rates (IRs, pts with events/100 pt-years) ≥ 5 were evaluated up to Month (M)3. Infections, laboratory test abnormalities, general disorders or events not directly reported by pts, and musculoskeletal disorders likely due to underlying RA, were excluded.

Results: Of the 2657 pts included in the analysis, 1976 received tofacitinib 5 mg BID (monotherapy: N=627; combination: N=1349) and 681 received PBO (monotherapy: N=122; combination: N=559). The most frequent non-serious AEs up to M3 are shown in the Table. IRs ≥ 10 were seen for headache and diarrhoea (tofacitinib 5 mg BID monotherapy, combination therapy and PBO monotherapy), and nausea (PBO monotherapy and PBO combination therapy). Non-serious AE duration was ≤ 4 weeks for most pts with headaches, diarrhoea or gastric discomfort (any gastrointestinal pain, dyspepsia, epigastric discomfort or abdominal discomfort/pain). With tofacitinib 5 mg BID and PBO, respectively, duration of AEs was ≤ 2 weeks for 43.2% and 64.7% of pts with headaches; 66.1% and 81.3% with diarrhoea; and 36.2% and 58.6% with gastric discomfort. Most non-serious AEs were mild/moderate.

Table. Non-infectious, treatment-emergent non-serious adverse events* in Phase 3 and Phase 3b/4 studies up to Month 3

Non-serious AE, n (%), IR [95% CI]	Monotherapy		Combination therapy		Overall	
	Tofacitinib 5 mg BID (N=627)	PBO ^b (N=122)	Tofacitinib 5 mg BID (N=1349)	PBO ^c (N=559)	Tofacitinib 5 mg BID (N=1976)	PBO ^{b,c} (N=681)
Headache	21 (3.3) 13.7 [8.5, 21.0]	3 (2.5) 10.1 [2.1, 29.4]	50 (3.7) 15.3 [11.3, 20.1]	13 (2.3) 9.5 [5.1, 16.3]	71 (3.6) 14.8 [11.3, 18.6]	16 (2.3) 9.6 [5.3, 15.6]
Diarrhoea	18 (2.9) 11.7 [7.0, 18.5]	3 (2.5) 10.0 [2.1, 29.2]	41 (3.0) 12.5 [8.9, 16.9]	13 (2.3) 9.5 [5.1, 16.3]	59 (3.0) 12.2 [9.3, 15.8]	16 (2.3) 9.6 [5.3, 15.6]
Nausea	15 (2.4) 9.8 [5.5, 16.1]	3 (2.5) 10.0 [2.1, 29.2]	29 (2.1) 8.8 [5.9, 12.6]	15 (2.7) 11.0 [6.2, 18.2]	44 (2.2) 9.1 [6.6, 12.2]	18 (2.6) 10.8 [6.4, 17.1]
Vomiting	7 (1.1)	2 (1.6)	18 (1.3) 5.4 [3.2, 8.6]	8 (1.4) 5.8 [2.5, 11.4]	25 (1.3) 5.1 [3.3, 7.6]	10 (1.5) 6.0 [2.9, 11.0]
Dyspepsia	4 (0.6)	4 (3.3)	20 (1.5) 6.0 [3.7, 9.3]	7 (1.3) 5.1 [2.1, 10.5]	24 (1.2)	11 (1.6)
Abdominal pain upper	7 (1.1)	0 (0.0)	17 (1.3) 5.1 [3.0, 8.2]	6 (1.1) 4.4 [1.6, 9.5]	24 (1.2)	6 (0.9)

*Defined as AEs with an IR (pts with events per 100 pt-years) ≥ 5 in at least one treatment group under monotherapy, combination therapy or overall therapy. IRs (and 95% CI) that did not meet this criterion (ie. IR < 5) are not shown. ^bPts receiving PBO without background csDMARDs in ORAL Solo (only concomitant antimalarial medications were allowed). ^cIncludes pts receiving PBO with background csDMARDs in Phase 3 and Phase 3b/4 studies. AE, adverse event; BID, twice daily; CI, confidence interval; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IR, incidence rate; PBO, placebo; pt, patient

Figure 1